Resistant hypertension is a condition where blood pressure remains elevated despite the use of three or more antihypertensive medications, including a diuretic. It accounts for approximately 31% of apparent treatment-resistant hypertension cases, based on a pooled estimate from various studies. Resistant hypertension pipeline analysis by Expert Market Research highlights a significant presence of small molecules, peptides, and RNA-based drugs. The growing focus on personalized treatment, novel drug classes, and improved diagnostic tools is accelerating the development of resistant hypertension therapeutics. With increased awareness, technological advancements, and unmet clinical needs, the pipeline is expected to grow significantly in the coming years.
Major companies involved in the resistant hypertension pipeline analysis include AstraZeneca, E-Star BioTech, LLC, and others.
Leading drugs currently in the pipeline include Minocycline Hydrochloride, Baxdrostat, MANP, and others.
Advancements in RNA-based molecules regulating renin-angiotensin activity, biologics targeting vascular inflammation, and compounds modulating sympathetic overactivity are expected to support the resistant hypertension pipeline expansion.
The Resistant Hypertension Pipeline Insight Report by Expert Market Research gives comprehensive insights into resistant hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for resistant hypertension. The resistant hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The resistant hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with resistant hypertension treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to resistant hypertension.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Resistant hypertension is a form of high blood pressure that remains above target levels despite adherence to a regimen of at least three antihypertensive medications of different classes, including a diuretic. It often results from factors such as excessive sodium intake, obesity, kidney disease, or secondary causes like hormonal imbalances, and it increases the risk of cardiovascular complications.
Resistant hypertension treatment includes optimizing current medications, adding aldosterone antagonists, or using novel agents such as endothelin-receptor antagonists to improve blood pressure control in patients unresponsive to standard therapy. In March 2024, the U.S. Food and Drug Administration approved Aprocitentan, marketed as Tryvio, as the first endothelin-receptor antagonist for resistant hypertension. It demonstrated significant blood pressure reduction when added to standard therapies in a randomized trial involving 730 patients.
Hypertension affects a large population, with regional prevalence in India ranging from 19.5% in the Eastern region to 27.9% in the Southern region. Men generally show higher rates than women. Resistant hypertension impacts 12.8% of the public and up to 40.4% of those with chronic kidney disease. It significantly increases cardiovascular and renal risks. Medication nonadherence, observed in 31% of cases, remains a key challenge in effective treatment. Continued innovation in targeted therapies is essential to improve outcomes in this high-risk population.
This section of the report covers the analysis of resistant hypertension drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 33.33%, covers a major share of the total resistant hypertension clinical trials, highlighting strong mid-stage development activity and therapeutic innovation in the pipeline. Phase IV follows with 22.22%, phase III at 18.52%, phase I at 11.11%, and early phase I at 7.41%. The balanced progression across phases reflects steady advancement, indicating a positive outlook for enhanced treatment solutions for resistant hypertension.
The drug molecule categories covered under the resistant hypertension pipeline analysis include small molecules, monoclonal antibodies, peptides, RNA-based molecules, and gene therapies. The resistant hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for resistant hypertension.
Aldosterone synthase inhibitors are emerging as a novel drug class in the resistant hypertension pipeline. For instance, Lorundrostat has demonstrated significant reductions in 24-hour systolic blood pressure in a Phase 2b trial. It directly inhibits aldosterone production, offering a more targeted mechanism with a favorable safety profile and fewer hormonal side effects.
The EMR report for the resistant hypertension pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed resistant hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in resistant hypertension clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for resistant hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of resistant hypertension drug candidates.
Minocycline Hydrochloride is being investigated in a Phase IV trial sponsored by the University of Florida for its potential to lower blood pressure in resistant hypertension. Known for its anti-inflammatory and neuroprotective effects, minocycline works by modulating the gut microbiota and reducing systemic and neuroinflammation. The study is examining its impact across racial groups and exploring gut-brain-immune axis mechanisms.
Baxdrostat by AstraZeneca is being evaluated in a Phase III trial to assess its effect on ambulatory blood pressure in patients with resistant hypertension. The study is examining the safety, tolerability, and efficacy of 2 mg oral Baxdrostat. It is a selective aldosterone synthase inhibitor targeting aldosterone reduction without impacting cortisol levels.
MANP is undergoing Phase 2 clinical development. The study is sponsored by E-Star BioTech, LLC, and aims to evaluate its safety and efficacy in patients with resistant hypertension. The trial is examining MANP’s impact on lowering daytime systolic blood pressure. MANP is a 40-amino acid designer natriuretic peptide that activates GC-A receptors, promoting natriuresis, vasodilation, and aldosterone suppression.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Resistant Hypertension Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for resistant hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into resistant hypertension collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share